Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics (Nasdaq: MLYS) announced that senior management will participate in fireside chats at three upcoming healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics (Nasdaq: MLYS) announced that senior management will participate in fireside chats at three upcoming healthcare investor conferences.
The sessions are scheduled for Guggenheim on November 10, 2026, at 2:30pm ET; Stifel on November 12 at 8:40am ET; and the 9th Annual Evercore Healthcare Conference on December 1 at 1:45pm ET. Live webcasts and archives will be available through the company’s Investor Relations News & Events page.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences.
| Guggenheim Healthcare Innovation Conference | |
| Date: | Tuesday, November 10, 2026 |
| Time: | 2:30pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
| Stifel Healthcare Conference | |
| Date: | Thursday, November 12, 2026 |
| Time: | 8:40am ET |
| Format: | Fireside Chat |
| Webcast Link | |
| 9th Annual Evercore Healthcare Conference | |
| Date: | Tuesday, December 1, 2026 |
| Time: | 1:45pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
The live webcasts and archives of these fireside chats can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.
Contact:
Investor Relations investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com
